Hemophilia Treatment Center

In accordance with KRS 200.550, the Commission for Children with Special Health Care Needs is required to establish a Hemophilia Treatment Program within the Commission for detection, diagnosis and treatment of persons suffering from Hemophilia. The Division of Pediatric Hematology/Oncology Center on behalf of the UK Hemophilia Treatment Center (UKHTC) has historically collaborated with the Commission in order to provide comprehensive hemophilia treatment services. This collaboration has been essential due to the complexity involved in maintining such services, both financially and resources based, for which the Commission would experience difficulty. In addition, Dr. Jeffrey Moscow at UK pharmacy management program has provided the outlet for obtaining FActor and managing its use. With the use of the pharmacy management program, the Commission has benefited by securing an outlet to supply our hemophilia patient's factor at a greatly reduced price on a statewide basis. This has eliminated the extreme cost associated with establishing a 340B Program to dispense Factor. Through supplementing the Dvision, the the UKHTC, with costs associated with maintaining a Hemophilia Treatment Program and 340B Program, the Commission for Childrenw ith Special Health Care needs has been provided with the foundation necessary to meet statute, while also avoiding the cost associated with establishing its own Hemophilia Treatment Program.